In Pandora Media news, CRO John Trimble sold 20,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $25.71, for a total transaction of $514,200.00. Following the transaction, the executive now directly owns 85,374 shares in the company, valued at approximately $2,194,966. Pandora Media Inc (NYSE:P) shares after opening at $25.50 moved to $25.87 on last trade day and at the end of the day closed at $23.51. Company price to sales ratio in past twelve months was calculated as 7.89 and price to cash ratio as 10.36. Pandora Media Inc (NYSE:P) showed a negative weekly performance of -12.99%.
Mylan Inc. (NASDAQ: MYL) announced that it has filed suit against the U.S. Food and Drug Administration (FDA), challenging the agency’s decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer’s Celebrex®. Mylan Inc (NASDAQ:MYL) shares advanced 3.48% in last trading session and ended the day on $5.10. MYL return on equity ratio is recorded as 20.90% and its return on assets is 4.80%. Mylan Inc (NASDAQ:MYL) yearly performance is 77.94%.
Analysts at Nomura reiterated a “reduce” rating on shares of Altera Corporation (NASDAQ:ALTR) in a research note on Friday. They now have a $30.00 price target on the stock. Separately, analysts at The Street downgraded shares of Altera from a “buy” rating to a “hold” rating in a research note on Thursday. Altera Corporation (NASDAQ:ALTR) shares moved down -3.08% in last trading session and was closed at $33.09, while trading in range of $ 32.67 – 35.50. Altera Corporation (NASDAQ:ALTR) year to date (YTD) performance is 2.26%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) company announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support its broad pipeline of immunotherapies and DNA vaccines. He will report to Inovio’s Chief Operating Officer Dr. Niranjan Sardesai. Prior to joining Inovio, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into successful commercial entities; he supported the growth of several pharmaceutical companies in the quality and compliance areas. Inovio Pharmaceuticals Inc (NYSEMKT: INO) weekly performance is -4.37%. On last trading day company shares ended up $2.41. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -24.75%. Analysts mean target price for the company is $4.60.